Symphogen
Executive Director of Research Institute and Global Head of External Research at Servier- In his role at Servier , Dr Christophe Thurieau is leading Servier’s Research centers and as head of external Research he is responsible for World Wide Research hubs to establish external strategic partnerships in R&D. Before joining Servier in April 2017 Dr Christophe Thurieau worked at Ipsen from 1996 to 2017. After different increasing roles and responsibilities within Research and Development at Ipsen, he was since 2009 President Ipsen Innovation and Senior Vice –President Global Scientific Affairs at Ipsen. He has authored more than 30 original research articles in international peer-reviewed scientific journal and holds 25 patents. Dr Christophe Thurieau obtained pre and post-doctoral training at Harvard medical school, Boston (U.S.) and received his Ph.D. in biochemistry from University Pierre and Marie Curie, Paris VI in 1988.
This person is not in any offices
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.